Largest biotech companies by cash on hand
Cash and cash equivalents at the end of the latest fiscal year. Short-term investments are not counted.
Amgen leads the 24 biotech companies ranked by cash on hand, at NOK 88.4B, ahead of BioNTech (NOK 82.4B) and Gilead Sciences (NOK 73.2B). Figures as of 18 Nov 2026, 22:14 UTC, from Yahoo Finance quotes.
Key facts
- Companies ranked
- 24
- First
- AmgenNOK 88.4B
- Median
- NOK 4.2B
- Combined market value
- NOK 8.1T
- Countries
- 5
Market values as of .
All countries▾
All sectors▾
Biotech▾
| # | Company | Cash on hand ↓ | Market cap | Price | Today | 1 year | Price, 30 days | Country |
|---|---|---|---|---|---|---|---|---|
| 1 | AmgenAMGN · Health Care | NOK 88.4B | NOK 2.32T | NOK 4,296.98 | 3.07% down | 34% up | ||
| 2 | BioNTechBNTX · Health Care | NOK 82.4B | NOK 199.8B | NOK 805.98 | 1.89% down | 16% down | ||
| 3 | Gilead SciencesGILD · Health Care | NOK 73.2B | NOK 2.03T | NOK 1,635.77 | 0.75% down | 33% up | ||
| 4 | argenxARGX · Health Care | NOK 33.8B | NOK 573B | NOK 9,111.55 | 0.66% down | 4% up | ||
| 5 | BiogenBIIB · Health Care | NOK 29.1B | NOK 359.8B | NOK 2,433.72 | 0.25% up | 49% up | ||
| 6 | ModernaMRNA · Health Care | NOK 25.1B | NOK 770.8B | NOK 1,904.98 | 4.84% down | 755% up | ||
| 7 | ImmunovantIMVT · Health Care | NOK 8.7B | NOK 66.4B | NOK 321.09 | 0.12% down | 43% up | ||
| 8 | QiagenQGEN · Health Care | NOK 8.1B | NOK 99.1B | NOK 479.75 | 0.38% down | 12% up | ||
| 9 | Neurocrine BiosciencesNBIX · Health Care | NOK 6.9B | NOK 159.6B | NOK 1,576.53 | 1.84% down | 20% up | ||
| 10 | RepligenRGEN · Health Care | NOK 5.5B | NOK 106.8B | NOK 1,671.49 | 6.47% up | 5% up | ||
| 11 | Krystal BiotechKRYS · Health Care | NOK 4.8B | NOK 90.5B | NOK 3,052.58 | 5.62% up | 46% up | ||
| 12 | ExelixisEXEL · Health Care | NOK 4.7B | NOK 161.3B | NOK 661.07 | 0.31% down | 63% up | ||
| 13 | Revolution MedicinesRVMD · Health Care | NOK 3.7B | NOK 334.6B | NOK 1,547.10 | 1.76% down | 131% up | ||
| 14 | Kymera TherapeuticsKYMR · Health Care | NOK 3.5B | NOK 100.1B | NOK 1,172.57 | 0.32% down | 87% up | ||
| 15 | CRISPR TherapeuticsCRSP · Health Care | NOK 3.4B | NOK 37.7B | NOK 389.05 | 0.10% up | 21% down | ||
| 16 | Scholar Rock HoldingSRRK · Health Care | NOK 3.1B | NOK 56.7B | NOK 464.65 | 6.48% up | 14% up | ||
| 17 | Bio-TechneTECH · Health Care | NOK 2.6B | NOK 110.6B | NOK 704.24 | 0.17% up | 26% up | ||
| 18 | Kodiak SciencesKOD · Health Care | NOK 2B | NOK 61.9B | NOK 946.83 | 1.04% up | 396% up | ||
| 19 | Twist BioscienceTWST · Health Care | NOK 1.8B | NOK 76.8B | NOK 1,126.30 | 3.88% up | 340% up | ||
| 20 | VaxcytePCVX · Health Care | NOK 1.7B | NOK 89.7B | NOK 566.49 | 1.48% down | 22% up | ||
| 21 | Halozyme TherapeuticsHALO · Health Care | NOK 1.3B | NOK 105.7B | NOK 927.37 | 0.18% down | 37% up | ||
| 22 | ImmunityBioIBRX · Health Care | NOK 855.1M | NOK 69B | NOK 64.86 | 7.03% up | 193% up | ||
| 23 | Adaptive BiotechnologiesADPT · Health Care | NOK 682.4M | NOK 44.6B | NOK 275.50 | 0.11% down | 88% up | ||
| 24 | CG OncologyCGON · Health Care | NOK 314.5M | NOK 69.2B | NOK 774.42 | 1.34% up | 85% up |
Sources: share prices and market values from Yahoo Finance; sector, country and category from each company's SEC registration; annual figures from the reports companies file with the SEC.
Market value is share price × shares outstanding, from Yahoo Finance; prices may be delayed 15 minutes or more and the ranking refreshes about every 20 minutes. The list covers companies with shares listed in the US, which includes foreign companies listed through ADRs but not ones listed only abroad. Sector, category and country come from each company's SEC registration. Cash on hand is from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day, not of the period. Sums are converted from US dollars at today's exchange rate (1 USD = 9.6803 NOK).
Questions and answers
Which biotech companies rank first by cash on hand?
Amgen (NOK 88.4B), BioNTech (NOK 82.4B) and Gilead Sciences (NOK 73.2B) are the top three of the 24 biotech companies ranked by cash on hand as of 18 Nov 2026, 22:14 UTC.
How many biotech companies are in this ranking?
24 are ranked by cash on hand.
What are these biotech companies worth together?
The 24 biotech companies ranked by cash on hand have a combined market value of NOK 8.1T as of 18 Nov 2026, 22:14 UTC.
What does ranking by cash on hand measure?
Cash and cash equivalents at the end of the latest fiscal year. Short-term investments are not counted.
Learn how this ranking works
All markets guides →- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Market cap vs enterprise value: what is the difference?
Market capitalization is the value of a company's shares. Enterprise value is market cap plus debt, minus cash: roughly what it would cost to buy the whole business and settle its borrowings. Two companies with the same $50 billion market cap can have very different enterprise values if one owes $20 billion and the other holds $20 billion in cash.
- How an ETF's size is measured: AUM, NAV and creation units
An ETF's size is usually measured by its assets under management (AUM), the fund's net assets: everything it holds minus what it owes. That equals net asset value per share times shares outstanding. AUM grows when the holdings rise in value and when large institutions create new shares, and shrinks when they redeem them.
Cite this page
Funkfolio, “Largest biotech companies by cash on hand”, data as of 18 November 2026. https://funkfolio.com/companies/category/biotech?by=cash-on-hand
Underlying data: Yahoo Finance; SEC EDGAR.